Skip to main content
. Author manuscript; available in PMC: 2022 Jan 29.
Published in final edited form as: Nat Cancer. 2021 Jul 29;2(9):891–903. doi: 10.1038/s43018-021-00234-4

Extended Data Fig. 8. Treatment alters levels of immunomodulatory chemokines in plasma.

Extended Data Fig. 8

Concentrations (pg/ml) of MIG (CXCL9), IP-10 (CXCL10), I-TAC (CXCL11), MCP-1 (CCL2), Eotaxin-3 (CCL26), Rantes (CCL5), MCP-2 (CCL8), and MIP-1a (CCL3) in longitudinally obtained plasma samples are shown as line graphs. All correlates were measured by Luminex multiplex assays. Data representative of two technical replicates. Each line represents an individual patient. Red and blue lines reflect pathologic non-responders and responders, respectively. All comparisons not statistically significant by FDR-adjusted P values (<0.05 considered significant, paired two-tailed t-tests).